While epalrestat has a beneficial role in ameliorating phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG) [28,29], the efficacy of epalrestat is undergoing assessment in the clinical trial of PMM2-CDG (NCT04925960). This evidence concerns the gene PMM2 and congenital disorder of glycosylation.